AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$EDIT

O'Neill Gilmore Neil sold $16K of EDIT

O'Neill Gilmore Neil (CEO) sold 5,124 shares of Editas Medicine, Inc. (EDIT) at $3.04 on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'Neill Gilmore Neil
Published Sep 4, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EDIT
Neutral
high confidence
Mentioned
$EDIT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EDITNeutralLow
01

Why it matters

The transaction is a routine insider sale under a pre‑arranged plan, with limited market impact.

02

Market read

Low relevance; small insider sale unlikely to affect stock price.

03

What to watch

Potential upcoming corporate events not disclosed could be the real driver of the sale.

Relevance 2/10Novelty 3/10Timing: filed Sep 4 2026

Background

SEC Form 4 filing reporting an insider transaction for Editas Medicine.

Company-level read

Ticker impact

$EDITNeutralHigh confidence
Context

CEO O'Neill Gilmore Neil sold 5,124 shares for $15.6K via a 10b5-1 plan, reducing his holdings to 243,189 shares.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

The sale size is small relative to float and disclosed via a pre‑arranged plan, so market reaction is expected to be negligible.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

Even small insider sales can signal confidence issues, but given the 10b5‑1 plan this is likely routine.

Key entities

  • Company
    Editas Medicine, Inc.

    Biotech firm listed on Nasdaq under ticker EDIT.

  • Person
    O'Neill Gilmore Neil

    CEO of Editas Medicine.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EDIT insider trading history →

Related articles

OCT 28
$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.com2 min
OCT 9
$EDITMedAI 8/10

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

Editas Medicine received approval to begin a phase I/II study for EDIT-401, a gene-editing therapy for heterozygous familial hypercholesterolemia, in Australia. The study aims to evaluate safety, tolerability, and efficacy, with dosing expected to start in 2026. EDIT-401 targets LDL cholesterol through gene editing, potentially offering long-lasting reductions. The company's stock has risen 38.5% year-to-date, outperforming the industry.

zacks.com2 min
OCT 8
$EDITMedAI 8/10

Wells Fargo Upgrades Editas Medicine (EDIT) on Phase 1/2 Trial A

Wells Fargo upgraded Editas Medicine (EDIT) to Overweight, raising its price target to $6 from $4. This follows the company's approval to start a Phase 1/2 trial for EDIT-401 in Australia, targeting a genetic condition. Editas has a P/S ratio of 6.15, below its historical median of 33.7x, and a GF Score of 51/100, indicating moderate fundamentals with weak profitability and financial strength.

gurufocus.com2 min